SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

*(Incorporated in the Cayman Islands with limited liability)*
*Website: www.sbpgroup.com*
**(Stock code: 1177)**

# VOLUNTARY ANNOUNCEMENT
# FURTHER DEEPENING OF
# THE EXCLUSIVE STRATEGIC COLLABORATION WITH GSK

The board of directors (the "**Board**") of the Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announced that Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ("**CTTQ**"), a subsidiary of the Company, further deepened the exclusive strategic collaboration with GlaxoSmithKline ("**GSK**"), building on the agreement entered into in May 2026, with a view to accelerating patient access to two blockbuster innovative respiratory therapies across China.

Pursuant to the terms of the agreement, the Group will obtain the commercialisation rights in mainland China for two innovative respiratory products of GSK: fluticasone furoate, umeclidinium, and vilanterol inhalation powder (FF/UMEC/VI, brand name: 全再樂®, Trelegy Ellipta®) and umeclidinium and vilanterol inhalation powder (UMEC/VI, brand name: 歐樂欣®, Anoro Ellipta®). The Group will be responsible for importation, distribution, hospital access, and promotional and non-promotional activities for these products in mainland China. Revenue generated from product sales in China is expected to be recognised by CTTQ.

This collaboration represents another key milestone in the Group's strategic collaboration with GSK, expanding the collaboration from liver diseases into respiratory diseases. The Group will work closely with GSK to ensure a smooth rollout across all aspects, including supply, commercialisation and compliance, while safeguarding patient access to medicines and continuity of care in China. Leveraging its strong commercial capabilities, the Group will further expand patient reach and market penetration of these medicines, accelerating sales growth and benefiting more patients in China.

As a leading player in China's respiratory field, the Group possesses a well-established, specialised sales team with deep market roots. It has established the largest innovative respiratory pipeline in China, covering novel targets including TSLP, P2X3, ROCK2, ST2, with in-house capabilities across multiple inhalation device platforms, including nebulizers, dry powder inhalers (DPIs), and soft mist inhalers (SMIs). The pipeline spans a broad range of major respiratory indications, such as chronic obstructive pulmonary disease (COPD), asthma, idiopathic pulmonary fibrosis (IPF) and rhinitis. The two blockbuster innovative products introduced through this collaboration are expected to not only directly increase the Group's revenue and profit, but also significantly accelerate its growth. Moreover, these products are highly synergized with the Group's existing pipeline, helping to further enrich its respiratory portfolio and strengthen its brand competitiveness. This will lay a solid foundation for the smooth launch and commercialisation of more in-house innovative products in the future, thereby further consolidating the Group's market leadership in China's respiratory sector.

To date, the Group has successively entered into strategic collaborations with a number of multinational pharmaceutical companies across core therapeutic areas such as oncology, hepatology and respiratory diseases. This not only reflects strong recognition of the Group's commercial capabilities, compliance governance and operational efficiency in the Chinese market, but also serves as a robust validation of the Group's integrated capabilities across the entire product lifecycle, from R&D and regulatory filing through to commercialisation. Looking ahead, the Group will continue to deepen its strategic collaborations with multinational pharmaceutical companies, striving to become the preferred partner for global pharmaceutical companies in China.

**About FF/UMEC/VI (brand name: 全再樂®, Trelegy Ellipta®)**

FF/UMEC/VI is a combination of three molecules in a single inhaler that only needs to be taken in a single inhalation, once a day. It contains fluticasone furoate (FF), an inhaled corticosteroid (ICS), umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA); and vilanterol (VI), a long-acting beta2-adrenergic agonist (LABA).

FF/UMEC/VI was first approved in China in 2019 for maintenance treatment of COPD, and in 2026, it received approval for an additional indication for maintenance treatment of asthma, becoming the first and the only single-inhaler triple therapy (SITT) in China indicated for maintenance treatment of both asthma and COPD. In 2025, the global sales of FF/UMEC/VI reached £3 billion.

**About UMEC/VI (brand name: 歐樂欣®, Anoro Ellipta®)**

UMEC/VI is a combination of two molecules in a single inhaler that only needs to be taken in a single inhalation, once a day. It contains umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA), and vilanterol (VI), a long-acting beta2-adrenergic agonist (LABA).

UMEC/VI was approved in China in 2018 for long-term maintenance treatment of COPD. In 2025, the global sales of UMEC/VI reached £542 million.

**About COPD and Asthma**

COPD and asthma are the most prevalent chronic respiratory diseases in China, characterised by a large patient population, prolonged disease duration, heavy disease burden, and the need for long-term standardised management. The total number of COPD patients exceeds 100 million, and the total number of asthma patients is close to 50 million in China[1, 2]. These diseases require long-term medication, regular follow-up, and on-going patient education, placing high demands on drug accessibility, treatment convenience, and the quality of disease management. In 2024, COPD was formally incorporated into the Chronic Disease Management under the *National Basic Public Health Services Programme* in China, becoming the third major chronic disease included in this program after hypertension and diabetes. This policy shift not only elevates COPD prevention and treatment to a national public health priority, but it is also expected to significantly improve early screening rates, promote standardised treatment practices, and enhance long-term adherence. In turn, this will accelerate the conversion of patients from the "potential treatment population" to the "active medication-taking population", unlocking substantial incremental market opportunities for innovative respiratory therapies.

**Regarding the Exclusive Strategic Collaboration with GSK**

On 11 May 2026, the Group announced an exclusive strategic collaboration with GSK to accelerate bepirovirsen in mainland China at launch. On 8 July 2026, the Group announced the deepening of its exclusive strategic collaboration with GSK to accelerate two blockbuster innovative respiratory therapies, FF/UMEC/VI (brand name: 全再樂®, Trelegy Ellipta®) and UMEC/VI (brand name: 歐樂欣®, Anoro Ellipta®), to benefit more patients in China.

Pursuant to the agreement, both parties will also have the opportunity to further explore broader collaboration opportunities relating to the Group's innovative R&D pipeline assets outside China. The collaboration is expected to support the establishment of a long-term strategic relationship between the two parties and lay a strong foundation for future collaboration on innovative therapies.

Sources:

[1] Wang C. et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study (2018) The Lancet 2018; 391 (10131).

[2] Huang, Kewu et al. "Prevalence, risk factors, and management of asthma in China: a national cross-sectional study." Lancet (London, England) vol. 394, 10196 (2019): 407–418. doi:10.1016/S0140-6736(19)31147-X

By order of the Board
**Sino Biopharmaceutical Limited**
**Tse, Theresa Y Y**
*Chairwoman*

Hong Kong, 8 July 2026

*As at the date of this announcement, the Board of the Company comprises five executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and Mr. Tse Hsin and six independent non-executive directors, namely Mr. Lu Zhengfei, Ms. Lu Hong, Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.*